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Abstract  
The purpose of this multicenter, prospective, randomized, placebo-controlled study was to 
evaluate and compare the efficacy of two cognitive rehabilitation interventions (Memory and 
Attention Adaptation Training (MAAT) and Attention Builders Training (ABT)), with and 
without pharmacologic enhancement (i.e., with methylphenidate (MPH) or placebo), for treating 
persistent cognitive problems after traumatic brain injury (TBI). Adults with a history of TBI at 
least four months prior to study enrollment with either objective cognitive deficits or subjective 
cognitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding 
four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), 
and ABT/placebo (N=18). Assessments were conducted pre-treatment (baseline) and after six 
weeks of treatment (post-treatment). Outcome measures included scores on neuropsychological 
measures and subjective rating scales. Statistical analyses used linear regression models to 
predict post-treatment scores for each outcome variable by treatment type, adjusting for relevant 
covariates. Statistically significant (p<0.05) treatment-related improvements in cognitive 
functioning were found for word list learning (MAAT/placebo>ABT/placebo), nonverbal 
learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working 
memory and divided attention (MAAT/MPH>ABT/MPH). These results suggest that combined 
treatment with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve 
aspects of attention, episodic and working memory, and executive functioning after TBI.  
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Introduction 
 
Functionally important cognitive impairments are common in the late period following traumatic 
brain injury (TBI). Working and episodic memory, attention, speed of information processing, 
and aspects of executive functioning are among the most common post-traumatic cognitive 
impairments, and are typical targets of rehabilitative efforts (Cappa et al, 2005; Cicerone et al, 
2011). Treatment of cognitive complaints and deficits in individuals with TBI has taken the form 
of either cognitive rehabilitation or pharmacologic augmentation.  
 
The two principal approaches to cognitive rehabilitation after TBI include remediation and 
compensatory training. Remediation (“cognitive retraining”) approaches are based on the theory 
that cognitive abilities can be improved by activating particular aspects of the cognitive process 
through graded mental exercise (Sohlberg et al, 2003; Tate, 1997). The techniques employed in a 
remediation approach often focus on repetitive practice regimens within a specific cognitive 
domain. Work using the Attention Process Training (APT) intervention has shown significant 
improvements on measures of objective and subjective attentional and executive functioning 
after TBI (Palmese and Raskin, 2000; Sohlberg et al, 2000). Similarly, treatments targeting 
“working attention” have been shown to improve performance on objective measures of attention 
as well as reduce self-reported attentional difficulties in daily functioning (Cicerone, 2002).  
 
Compensatory training approaches focus on adapting to and compensating for cognitive 
impairment by capitalizing on remaining cognitive strengths and functional abilities. Many such 
approaches incorporate “metacognitive training” using cognitive domain-specific compensatory 
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techniques and evidence-based remediation techniques (where available) in order to develop 
strategies to improve performance and generalization of skills to daily tasks. Such metacognitive 
approaches can include training in cognitive strategy use, self-monitoring, self-regulation, and 
therapist feedback (Cicerone et al, 2011). Systematic reviews and meta-analyses have suggested 
that the evidence for the efficacy of such interventions is sufficiently strong to rise to the level of 
a practice guideline for treatment of cognitive deficits after TBI, and that inclusion of 
metacognitive training strategies is likely to be more effective than direct attention training alone 
(Cicerone et al, 2011). 
 
Pharmacotherapy of cognitive complaints and deficits generally targets major neurotransmitter 
systems modulating the function of brain regions underlying the relevant cognitive process (e.g., 
attention, working or episodic memory). Both human and animal studies suggest that the neural 
circuitry and neurochemistry of different components of memory and attention overlap 
significantly, and involve broad networks of brain regions including bilateral prefrontal and 
parietal cortices, cingulate gyrus, basal ganglia, hippocampus and related mesial temporal 
structures, and regions of the brain stem and midbrain forming the reticular activating system 
(Arciniegas et al, 2013). Cerebral catecholamines, as well as catecholaminergic-
acetylcholinergic interactions, modulate the function of several of these large-scale distributed 
networks, which subserve attention, episodic and working memory, and executive control of 
these cognitive functions, and in which the dorsolateral and inferolateral prefrontal cortices are 
critical nodes (Arciniegas, 2013). 
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Methylphenidate (MPH) augments cerebral dopaminergic and adrenergic systems. Evidence 
suggests that MPH improves performance on measures of attention, memory, verbal fluency, 
processing speed, motor performance, and arousal, and is also associated with improvements in 
subjective (self or informant) assessment of cognitive functioning (Gualtieri and Evans, 1988; 
Johansson et al, 2015; Kaelin et al, 1996; McAllister et al, 2015; Plenger et al, 1996; Whyte et 
al, 1997; Whyte et al, 2004; Whyte et al, 2002; Willmott and Ponsford, 2009). Indeed, the 
Defense and Veterans Brain Injury Center’s Neurobehavioral Guidelines Working Group 
evidence-based review of pharmacotherapies for post-traumatic cognitive impairments 
recommended MPH at the Guideline level for attention and processing speed impairments, and at 
the Option level for general cognitive deficits and memory impairments (Warden et al, 2006). 
More recent meta-analyses also concluded that the evidence supports MPH as a treatment for 
attention impairments, including working memory impairments, after TBI (Huang et al, 2016; 
Wheaton et al, 2011). MPH therefore appears to be a promising agent for remediation of 
persistent cognitive deficits after TBI. 
 
The available literature suggests that domain-specific evidence-based cognitive rehabilitation 
and symptom-targeted pharmacotherapy can improve cognitive problems after TBI. Preliminary 
reports suggest that pharmacologic facilitation of brain injury rehabilitation may improve 
cognitive outcomes (Berthier et al, 2009; Bragoni et al, 2000); however, few studies examine the 
efficacy of pharmacologically facilitated cognitive rehabilitation, and none have focused 
specifically on this approach to the treatment of cognitive impairments in the late period 
following TBI. This study implemented a double-blind, placebo-controlled trial of the 
effectiveness of two forms of cognitive rehabilitation (remediation and compensatory training) 
©    2016 Macmillan Publishers Limited. All rights reserved.
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and MPH, alone and in combination, to treat cognitive symptoms after TBI. We hypothesized a 
synergistic effect, such that participants receiving MPH and a compensatory training intervention 
would show greater improvement than those receiving other treatment combinations. Based on 
the available literature, we focused on outcome measures testing attention-related functions, 
including working memory and processing speed. As downstream effects of improved attention 
can also result in better performance in other cognitive domains, we also examined episodic 
memory and executive function.   
©    2016 Macmillan Publishers Limited. All rights reserved.
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Patients and Methods 
 
Design and Participants 
 
Overview: This double-blind, placebo-controlled, 2x2 factorial design tested the efficacy of 
pharmacotherapy, cognitive rehabilitation, and combination therapies for persistent cognitive 
symptoms and/or deficits after TBI in a six-week trial (ClinicalTrials.gov Identifier 
NCT00453921). Participants gave written informed consent approved by the Institutional 
Review Boards of Dartmouth-Hitchcock Medical Center, Indiana University School of 
Medicine, and University of Colorado School of Medicine.  
 
Inclusion criteria: (1) age 18-65 at study entry (2) TBI of at least mild severity (Kay et al, 1993) 
at least 4 months prior to study entry; and (3) self-report of cognitive deficits as a result of the 
injury of sufficient severity to interfere with social and/or occupational functioning as measured 
by a score at least one standard deviation above the normative mean on the Multiple Abilities 
Self-Report Questionnaire (MASQ) (Ahles et al, 2008; Seidenberg et al, 1994), and/or objective 
evidence of cognitive deficits represented by either (a) score two or more standard deviations 
below age-adjusted normative data or estimates of premorbid function (Barona et al, 1984) on 
one or more tests of attention and/or memory, or (b) score one or more standard deviations below 
either age-adjusted normative data or estimates of premorbid function on two or more tests of 
attention and/or memory administered as part of the screening cognitive battery. 
 
©    2016 Macmillan Publishers Limited. All rights reserved.
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Exclusion criteria: (1) history of other neurologic or systemic medical disorder that was 
unstable, likely to need repeated medication adjustments, or likely to affect cognitive function or 
be a contraindication to use of MPH; (2) current DSM-IV (APA, 2000) Axis I diagnosis of 
psychiatric illness, other than mild-moderate depression or anxiety, screened for using the Mini-
International Neuropsychiatric Interview (M.I.N.I. English Version 6.0.0, modified based on the 
version for ADHD studies) (Sheehan et al, 1998), Beck Depression Inventory-II (Beck et al, 
1996), State-Trait Anxiety Inventory (Spielberger, 1983), and PTSD Checklist-Stressor Specific 
(PCL-S) (Weathers et al, 1993); (3) currently pregnant or lactating; (4) pre-injury diagnosis of 
learning disability or attention-deficit/hyperactivity disorder (ADHD); (5) lack of English 
fluency sufficient to complete study measures; or (6) standard score below 70 on the Wide 
Range Achievement Test-4 Word Reading subtest (Wilkinson and Robertson, 2006), to ensure 
reading ability sufficient to participate in cognitive rehabilitation. 
 
Study Protocol: Eligible participants underwent a pre-treatment baseline assessment, then were 
randomized to receive MPH or placebo and one of two cognitive rehabilitation interventions, a 
metacognitive intervention, Memory and Attention Adaptation Training (MAAT, designed by 
R.J.F.), or Attention Builders Training (ABT), a manualized repetitive practice intervention with 
no active cognitive-behavioral component. This resulted in four treatment combinations: 
MAAT/MPH, ABT/MPH, MAAT/placebo, and ABT/placebo. Phone contacts (weeks 1, 3, and 
5) assessed for side effects and monitored compliance. At in-person study visits (weeks 2 and 4) 
participants also engaged in their assigned therapy (MAAT or ABT). After six weeks of 
treatment, participants completed post-treatment outcome measures (see Supplemental Figure 1 
for study flow).  
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Cognitive Assessment: The test battery emphasized cognitive domains most commonly reported 
as impaired after TBI, including memory, attention-related and executive functions, and 
processing speed, and included measures of general cognitive ability for sample characterization. 
Cognitive eligibility screening included the California Verbal Learning Test-II (Delis et al, 
2000), Delis-Kaplan Executive Function System (Delis et al, 2001) Trail Making, Verbal 
Fluency, and Color-Word Interference subtests, Paced Auditory Serial Addition Test (Gronwall, 
1977), Wechsler Adult Intelligence Scale-III (The Psychological Corporation, 1997) Letter 
Number-Sequencing Test, and Gordon Diagnostic System Continuous Performance Test 
(Gordon et al, 1996). Assessments at the pre-treatment visit included the Vocabulary and Block 
Design subtests of the Wechsler Abbreviated Scale of Intelligence (The Psychological 
Corporation, 1999), Wechsler Adult Intelligence Scale-III Digit Symbol-Coding and Digit Span 
subtests, Delis-Kaplan Executive Function System Sorting Test, Craft Story Memory Test (Craft 
et al, 1996), Brown Location Test (Brown et al, 2007), Grooved Pegboard Test (Lafayette 
Instrument, 1989), Finger Tapping Test (Reitan and Wolfson, 1993), and Thumb-Finger 
Sequencing Test (Saykin et al, 1995). The complete neuropsychological battery and the MASQ 
were repeated at post-treatment, with alternate test forms used where possible.  
 
Interventions 
 
Memory and Attention Adaptation Training (MAAT): MAAT is a brief cognitive-behavioral 
therapy aimed at enhancing skills for self-managing and coping with cognitive failures in daily 
life. Initially developed for use in patients experiencing postconcussive symptoms (Ferguson and 
©    2016 Macmillan Publishers Limited. All rights reserved.
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Mittenberg, 1996), MAAT was later adapted for treatment of cognitive symptoms after breast 
cancer chemotherapy, where preliminary data showed good feasibility and acceptability and 
beneficial treatment outcomes (Ferguson et al, 2007; Ferguson et al, 2012). The version of 
MAAT used in this study consisted of four biweekly 50-minute individual office visits focused 
on cognitive-behavioral strategy use. Briefer telephone contacts between visits were intended to 
reinforce use of new behaviors or modify the strategy to enhance effectiveness.  
 
MAAT includes four cognitive-behavioral components: (1) Education regarding “normal” 
cognitive failures, as well as potential effects of TBI on cognitive function; (2) self-awareness 
training to identify “at-risk” situations where cognitive failures are likely to occur; (3) self-
regulation training emphasizing applied relaxation techniques and stress management; and (4) 
cognitive compensatory strategy training. Each participant received a MAAT workbook with 
detailed descriptions of compensatory strategies, educational material, and guides on how to 
apply compensatory strategies. Clinicians followed a detailed manual to enhance treatment 
fidelity. R.J.F. trained and supervised therapists in conducting the MAAT treatment protocol, 
reviewed recordings of treatment visits, and provided corrective feedback as necessary.  
 
Attention Builders Training (ABT): ABT was modeled after Berg, Koning-Haanstra, and 
Deelman (Berg et al, 1991). Participants were provided information about cognitive remediation 
techniques related to the use of repetitive cognitive tasks to build skills through “mental 
exercise” (Tate, 1997), akin to the direct attention training approaches discussed above. Visit 
timing and duration were identical for ABT and MAAT. ABT also included an educational 
component discussing common cognitive symptoms after TBI, but did not emphasize behavioral 
©    2016 Macmillan Publishers Limited. All rights reserved.
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compensatory and functional reorganization strategies, nor was instruction provided on how to 
implement the exercises in daily living situations.  
 
At the initial therapy visit, participants were given an ABT manual and a packet consisting of a 
variety of tasks, which were carefully explained and practiced to ensure understanding. A 
repetitive practice regimen was assigned. Tasks were not tailored to the participant’s cognitive 
complaints/deficits, there was no “coaching” on the tasks, and no compensatory strategy training 
was provided. On subsequent visits the home-practice regimen was reviewed, refresher drills and 
practice sessions were performed, and new assignments were given. Phone contacts entailed 
evaluation of the home practice regimen by the therapist and empathetic listening without any 
instructions. 
 
Methylphenidate: Participants weighing <100 kg received MPH 0.1 mg/kg of body weight twice 
daily (BID) for 2-4 days, then 0.2 mg/kg BID for 2-4 days (default choice for both intervals was 
two days; study physicians could extend the titration interval to four days at their discretion), 
then 0.3 mg/kg BID for the remainder of the study. Doses were rounded to the nearest 2.5 mg 
increment. Those weighing >100 kg received doses of 10 mg BID, then 15 mg BID, then 30 mg 
BID for the same intervals. Therefore, dosing did not exceed 60 mg/day total. For an average 70 
kg adult, this translates into about 20 mg BID. This target dose was based on studies 
demonstrating efficacy in improving cognitive function in TBI populations (Plenger et al, 1996; 
Whyte et al, 1997; Whyte et al, 2002). Participants with modest side effects who wished to 
continue in the protocol were allowed dose reduction at physician discretion, but needed to be 
able to tolerate a dose of at least 10mg/day to remain in the study.  
©    2016 Macmillan Publishers Limited. All rights reserved.
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Placebo: Placebo was provided in capsules indistinguishable from the MPH capsules in taste and 
appearance, with BID dosing and similar titration increases (i.e., an increase in number of 
capsules of placebo). 
 
Randomization and Masking: Group assignment occurred through block randomization. Group 
allocation was concealed. Therapists were blind to outcome data, and staff conducting outcome 
assessments were blind to participant randomization. Medications were prepared and distributed 
by site-specific pharmacies which maintained the allocation code and ensured blinding of study 
medications.  
 
Adverse events and treatment compliance were monitored via phone contacts and at in-person 
visits, and by inventorying study capsules at in-person visits. 
 
Statistical Analysis: Demographic and clinical covariates were assessed for group differences 
using ANOVA or chi-square tests as appropriate. Primary outcome variables included measures 
of episodic memory (California Verbal Learning Test-II initial encoding over trials 1-5 number 
correct: CVLT), attention (Continuous Performance Test Distractibility trial reaction time: 
CPT_RT), divided attention and working memory (Paced Auditory Serial Addition Test Trial 3 
(1.6” pacing) number correct: PASAT), processing speed (Wechsler Adult Intelligence Scale-III 
Digit Symbol-Coding number correct: DSC; Delis-Kaplan Executive Function System Trail 
Making Test, trial 2 completion time: DTR2), and self-reported cognitive function (MASQ total 
score: MASQ). Secondary outcome measures included additional measures of episodic memory 
©    2016 Macmillan Publishers Limited. All rights reserved.
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(Craft Stories immediate recall total score: CRAFT; Brown Location Test initial encoding over 
trials 1-5 number correct: BLT), and executive function (D-KEFS Sorting Test free sorting 
description total score: SORT).  
 
All analyses were conducted using the R statistical software package (v3.1.2), as follows. Main 
effects of MAAT, MPH, and their interaction were examined via nonparametric Kruskal-Wallis 
test for changes between baseline and post-treatment measurements. Linear regression models 
were fit for post-treatment scores for each outcome variable for the primary factors of interest, 
cognitive rehabilitation (MAAT vs. ABT) and pharmacotherapy (MPH vs. placebo), together 
with their interaction, adjusting for baseline performance, study site, days since injury (log 
transformed), and treatment adherence (percent of prescribed doses taken). Post-treatment scores 
adjusted for covariates are referred to as “predicted” scores. For each treatment combination the 
estimated means were obtained at the average value of the adjustment variables. It was 
hypothesized that the MAAT/MPH group would show greater cognitive improvement than the 
other groups. A p-value <0.05 was considered to indicate statistical significance. Standardized 
(adjusted) coefficients and effect sizes (unadjusted) are reported. Standardized coefficients are 
estimated from the regression model used to predict post-treatment scores. To create comparable 
adjusted coefficients among outcome variables, both outcome and adjustment variables are 
standardized to have the mean equal to zero and standard deviation equal to one. Effect sizes 
(Cohen’s d) are estimated by the ratio of the difference between the post-treatment and baseline 
scores for each treatment combination and the pooled standard error estimate of the differences.  
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Results 
 
101 individuals consented to participate and were screened for eligibility; 76 were randomized to 
the four treatment arms (see CONSORT flow diagram (Figure 1)). One participant who 
completed the study was subsequently diagnosed with a confounding medical condition, and so 
was excluded from all analyses. Demographics and injury severity by treatment group are shown 
in Table 1. Time since injury for the 75 participants included ranged from five months to 35 
years. Forty-nine participants (65%) were eligible for the study based on both subjective and 
objective symptom entry criteria. Thirteen participants (17%) were eligible based on objective 
cognitive deficits, but did not have subjective cognitive complaints based on the MASQ 
threshold, and 13 participants (17%) were eligible based on MASQ score, but did not have 
objective cognitive deficits per the entry thresholds. Entry eligibility criteria met did not 
significantly differ by treatment group (p=0.44).  
 
Treatment groups did not significantly differ for age, education, race, ethnicity, handedness, sex, 
time since injury, or injury severity (all p>0.05). Four participants (one from each study arm) 
enrolled in the study and began treatment but chose not complete the trial, and so were not 
included in outcome analyses. This resulted in a final sample of 71 participants for analysis: 
MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18). 
Medication adherence and pre-treatment cognitive performance data are presented in 
Supplemental Table 1. Subjective and objective cognitive performance showed no significant 
differences between groups pre-treatment (all p>0.05), though the ABT/MPH group showed 
somewhat lower PASAT performance than the other groups (p=0.09). 
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Medication adherence and mean total daily dose of study medication did not differ significantly 
between treatment groups (both p>0.05). Vital signs, including blood pressure and heart rate, 
were checked at in-person visits and compared to pre-treatment measurements, and no clinically 
meaningful changes were noted. The two most common side effects, reported in >25% of the 
overall sample, were headache (47.1%) and insomnia (27.9%); frequency did not differ between 
patients receiving placebo and MPH (both p>0.05). Four symptoms were significantly more 
common in patients receiving MPH: nervousness, appetite loss, palpitations (all p<0.05), and 
abdominal discomfort (p<0.01). Side effects led to dose reduction for nine participants (including 
one who received placebo); dose reduction was significantly more common in patients receiving 
MPH (p<0.05). No participant withdrew from the study due to adverse events, and no serious 
adverse events were reported.  
 
As described under Statistical Analysis above, outcome variables were examined post-treatment 
for each treatment condition relative to the other three conditions, adjusting for pre-treatment 
performance, study site, time since injury, and treatment adherence. Predicted scores for all 
outcome variables are shown in Table 2, and between-group treatment-related comparison data 
are presented in Table 3. Raw scores for post-treatment cognitive performance can be found in 
Supplemental Table 2. For the primary outcome variables, at post-treatment the 
MAAT/Placebo group showed significantly higher CVLT performance relative to the 
ABT/Placebo group (p=0.040, Figure 2a). For PASAT, the MAAT/MPH group showed 
significantly higher performance than the ABT/MPH group (p=0.021, Figure 2b). For the 
secondary outcome variables, the MAAT/MPH group showed significantly higher BLT 
performance (Figure 2c) than both the MAAT/placebo (p=0.021) and ABT/MPH (p=0.030) 
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groups. No significant differences were seen for CRAFT, CPT_RT, DSC, DTR2, MASQ, or 
SORT.  
 
In addition to these significant results, moderate to large effect sizes (Table 3) were noted for 
some primary and secondary outcome variables where statistical tests demonstrated p values 
which did not rise to the a priori threshold of p<0.05. Tests yielding p<0.10 were examined to 
determine those additional measures which might have risen to statistical significance with a 
larger sample size. For the primary outcome variables, the MAAT/Placebo group showed higher 
CVLT performance (Figure 2a) relative to the ABT/MPH (p=0.063) and MAAT/MPH 
(p=0.070) groups. For the secondary outcome variables, the MAAT/MPH group showed higher 
performance than the ABT/placebo group on BLT (p=0.078, Figure 2c) and 
CRAFT (p=0.055, Figure 2d).  
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Discussion 
 
Persistent cognitive changes are among the most problematic symptoms after TBI, with potential 
negative effects on quality of life across multiple domains. Consistent with findings from prior 
studies, the current results suggest that cognitive rehabilitation (MAAT) and pharmacotherapy 
(MPH) may improve cognitive performance in individuals with chronic cognitive impairments 
and/or complaints after TBI. To our knowledge, this is the first study to examine the utility of 
cognitive rehabilitation and pharmacotherapy in combination; our results suggest that combining 
pharmacotherapy and cognitive rehabilitation treatments may achieve greater improvement in 
cognitive functioning after TBI than either treatment alone. 
 
For two of the outcomes examined (PASAT and BLT), patients who received a compensatory 
training intervention and MPH (the MAAT/MPH group) showed significantly stronger 
performance than other treatment groups, demonstrating a benefit for combined treatment in 
terms of performance on objective measures of learning, working memory, and divided attention. 
This finding is particularly important given that these domains are among those most commonly 
affected after TBI. On a measure of verbal learning (CVLT), the MAAT/placebo group showed 
significantly stronger performance than the ABT/placebo group. This finding offers evidence 
that a metacognitive (compensatory training) cognitive rehabilitation intervention is more 
beneficial for verbal encoding deficits than is a repetitive practice (remediation) treatment 
approach.  
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The present observations also suggest a possible synergistic effect of catecholaminergic 
augmentation and a metacognitive rehabilitation approach. Westbrook and Braver (Westbrook 
and Braver, 2016) summarize the role of dopamine in multiple aspects of cognition, including 
motivation, learning, working memory, and decision-making, and propose that dopamine’s role 
in regulating working memory has direct relevance for cognitive effort, due to involvement of 
the dopamine system in incentive (reward) processing. MPH works directly on the dopaminergic 
system by inhibiting dopamine reuptake. The metacognitive approach of MAAT emphasizes 
improving behavioral aspects of executive functioning. As metacognition is sensitive to 
dopaminergic modulation (Joensson et al, 2015), and metacognitive tasks also increase 
prefrontal dopamine (Westbrook et al, 2016), this may explain the relatively greater 
improvements seen in patients receiving both MPH and MAAT relative to metacognitive 
rehabilitation without MPH or repetitive practice treatment (i.e., ABT) with MPH. 
 
Among the strengths of the study are its design, the representativeness of the sample of 
individuals with persistent post-traumatic cognitive impairments residing in the community, and 
demonstration of treatment feasibility and acceptability. This double-blind, placebo-controlled 
study incorporated comparison conditions for both its pharmacotherapeutic (i.e., 
methylphenidate vs. placebo) and cognitive rehabilitation (i.e., MAAT vs. ABT) components. 
Our data suggest that the active cognitive-behavioral component of MAAT was more effective in 
generating gains in cognition than the repetitive practice approach of ABT, although the 
concurrent administration of placebo with both limits inferences that can be drawn about the 
relative intrinsic efficacies of these very different approaches to cognitive rehabilitation.  
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Participants were representative of individuals with TBI residing in three geographically distinct 
areas of the country (Northern New England, Midwest, Rocky Mountain Region). Inclusion 
criteria were relatively broad, and potential participants were only excluded for conditions likely 
to confound outcome measures or to present a potential safety risk. In addition, while the 
majority (59%) of participants experienced mild or complicated mild TBI, generally consistent 
with the preponderance of mild TBI in terms of overall incidence of injury severity, the study 
sample included good representation of moderate (11%) and severe (31%) injury as well. These 
factors increase the generalizability of the findings.  
 
We also demonstrated acceptable tolerability, safety, and treatment adherence (>90% on average, 
as noted above), with minimal attrition (5%) over the course of the trial. This suggests that the 
types of pharmacologically facilitated cognitive rehabilitation employed in this study are 
sufficiently acceptable to those with persistent post-traumatic cognitive impairments to merit 
further study in larger-scale efficacy and effectiveness trials. 
 
The principal limitation of the study is the small sample size. As has been noted in related 
literature, despite the need for interventional studies to address cognitive problems after TBI, 
recruitment for this and similar studies is extremely challenging (McAllister et al, 2015). The 
initial target for this study was to recruit 50 patients into each treatment group, for a total of 200 
participants. As reflected in the CONSORT diagram (Figure 1), 101 individuals were screened 
in person for this study. That number represents only about 10% of the total pool of individuals 
screened, the majority of whom were found to be ineligible after an initial phone screen. Of those 
who completed in-person screening, some otherwise eligible individuals were unwilling to 
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consider taking MPH, or unable to make the commitment required to participate in cognitive 
therapy.  
 
In the context of small sample size, the population heterogeneity mentioned above as a strength 
with regard to representativeness could also be considered a weakness in terms of factors which 
may influence effectiveness of treatment, such as injury severity, injury to treatment interval, and 
other such metrics. The sample also had very limited racial/ethnic diversity. We therefore are 
unable to comment on whether there are subgroups for whom individual treatments may be more 
effective than others, and whether or not duration of time since injury significantly impacts on 
improvement after intervention.  
 
Challenges in identifying and recruiting participants to treatment trials are unfortunately 
common in the field, making it extremely difficult to conduct definitive, appropriately powered 
trials to determine the efficacy of a given intervention. This study was initially designed as a 
single-center trial, but was expanded to be a multicenter study given the recruitment challenges. 
This was an early phase study with a targeted directional hypothesis, and we wanted to discover 
possible sensitive candidate outcomes. Therefore, no adjustments were made for multiple 
comparisons, and differences with an associated p value <0.05 were considered statistically 
significant. Additional studies replicating the present findings are needed, and such studies will 
likely also need to be multicenter trials in order to accrue sufficient numbers of participants. 
However, the presence of significant results and medium to large effect sizes in the current 
modest sample showing positive effects of combined cognitive rehabilitation and 
pharmacotherapy treatment for cognitive changes after TBI is highly encouraging, and suggests 
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that additional findings may have risen to statistical significance had the study been powered as 
initially intended.  
 
In summary, we demonstrated that combined treatment with a manualized cognitive 
rehabilitation approach and MPH resulted in modest but statistically significant improvements in 
cognitive functioning on measures of verbal and nonverbal learning, working memory, and 
divided attention in adults with persistent cognitive symptoms after TBI. While additional 
research is needed to replicate these promising initial findings, the current results provide support 
for multimodality treatment approaches to improve cognitive functioning even months to years 
after TBI. 
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Figure Legends 
Figure 1. CONSORT diagram of study subject flow. CONSORT flow diagram showing 
disposition of patients assessed for study eligibility. ABT=Attention Builders Training; 
MAAT=Memory and Attention Adaptation Training; MPH=methylphenidate 
 
Figure 2. Treatment group comparisons. Outcome variables showing between-group differences 
from pre- to post-treatment for: 2a) CVLT, 2b) PASAT, 2c) BLT, and 2d) CRAFT. Predicted 
Post-Treatment Scores are post-treatment performance adjusted for pre-treatment performance, 
study site, time since injury, and treatment adherence. CVLT=California Verbal Learning Test-
II; PASAT=Paced Auditory Serial Addition Test; BLT=Brown Location Test; ABT=Attention 
Builders Training; MAAT=Memory and Attention Adaptation Training; MPH=methylphenidate 
 
Supplemental Figure 1. Outline of participant flow through study visits, from screening 
procedures to assess eligibility through active treatment. ABT=Attention Builders Training; 
EKG=electrocardiogram; MAAT=Memory and Attention Adaptation Training; 
MPH=methylphenidate 
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Table 1. Demographic and Injury Characteristics  
 MAAT/MPH  
Mean (SD) or N (%) 
ABT/MPH  
Mean (SD) or N (%) 
MAAT/Placebo  
Mean (SD) or N (%) 
ABT/Placebo  
Mean (SD) or N (%) 
p 
Number Enrolled 
 
18 20 18 19  
Age  
 
43.1 (12.3) 43.0 (15.0) 37.2 (12.0) 37.3 (14.2) 0.33 
Education (years) 
 
15.1 (2.4) 15.4 (2.4) 14.7 (2.1) 14.1 (2.1) 0.30 
Years Post Injury 9.0 (8.5) 7.6 (10.3) 5.4 (7.5) 8.2 (10.1) 0.68 
 
Race 
     
0.52 
American Indian/ 
Alaska Native 
0 (0%) 0 (0%) 1 (5.6%) 0 (0%)  
African American  1 (5.6%) 1 (5.0%) 0 (0%) 0 (0%)  
White 17 (94.4%) 19 (95.0%) 17 (94.4%) 19 (100%)  
 
Not Hispanic  
or Latino 
 
 
17 (94.4%) 
 
20 (100%) 
 
18 (100%) 
 
18 (94.7%) 
 
0.55 
Right-handed 
 
17 (94.4%) 15 (75.0%) 16 (88.9%) 18 (94.7%) 0.19 
Male 8 (44.4%) 14 (70.0%) 14 (77.8%) 13 (68.4%) 0.17 
 
TBI severity 
     
0.42 
Mild 9 (50.0%) 10 (50.0%) 10 (55.6%) 7 (36.8%)  
Complicated Mild 4 (22.2%) 2 (10.0%) 1 (5.6%) 1 (5.3%)  
Moderate 2 (11.1%) 3 (15.0%) 2 (11.1%) 1 (5.3%)  
Severe 3 (16.7%) 5 (25.0%) 5 (27.8%) 10 (52.6%)  
p values are from ANOVA or chi-square tests as appropriate 
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Table 2. Predicted Post-Treatment Cognitive Performance Scores 
 MAAT/MPH  ABT/MPH  MAAT/Placebo  ABT/Placebo  
Sample Size (N) 
 
17 19 17 18 
CVLT-II Total Score 
Trials 1-5 
 
51.8 (2.1) 51.9 (1.9) 57.2 (2.0) 51.3 (1.9) 
CPT Distractibility Trial 
Reaction Time (msec) 
 
394.7 (17.3)
a
 416.6 (15.9)
a
 413.0 (17.3)
a 
 
426.4 (15.3) 
PASAT 1.6” Pacing 
Number Correct 
 
40.2 (1.4)
c
 35.7 (1.2)
a
 37.6 (1.3)
b
 38.6 (1.2)
b
 
WAIS-III Digit Symbol-
Coding Raw Score 
 
71.7 (2.5) 73.5 (2.4) 71.2 (2.5) 75.7 (2.4) 
D-KEFS Trail Making 
Number Sequencing 
Trial Time (sec) 
 
33.4 (2.3) 30.8 (2.2) 32.5 (2.3) 30.5 (2.2) 
MASQ Total Score 
 
120.5 (4.8) 114.1 (4.5) 118.1 (4.8) 116.4 (4.5) 
Craft Stories Immediate 
Recall Total Score 
 
51.4 (2.1) 48.6 (2.1)
b
 48.7 (2.2)
a
 45.4 (2.1)
a
 
BLT Total Score  
Trials 1-5 
 
41.1 (2.1) 34.9 (1.9) 34.3 (2.0) 36.0 (1.9) 
D-KEFS Sorting Test 
Free Sorting Description 
Score 
38.2 (2.1) 40.0 (2.0)
a
 37.9 (2.2)
a
 38.7 (2.0)
a
 
Values are Predicted Score (SE). CVLT-II=California Verbal Learning Test-II; CPT=Gordon Diagnostic 
System Continuous Performance Test; PASAT=Paced Auditory Serial Addition Test; WAIS-
III=Wechsler Adult Intelligence Scale-III; D-KEFS=Delis-Kaplan Executive Function System; 
MASQ=Multiple Abilities Self-Report Questionnaire; BLT=Brown Location Test 
a
 Data were missing for 1 participant  
b
 Data were missing for 2 participants 
c
 Data were missing for 3 participants  
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Table 3. Between-Group Treatment-Related Comparison Data 
 Adjusted R
2
 p Standardized 
Coefficient 
Cohen’s d 
Effect Size 
CVLT  0.548    
MAAT/Placebo-ABT/Placebo  0.040 0.491 0.792  
MAAT/Placebo-ABT/MPH  0.063 0.439 0.752  
MAAT/Placebo-MAAT/MPH  0.070 0.449 0.828  
 
PASAT 0.814    
MAAT/MPH-ABT/MPH  0.021 0.392 0.301 
  
CRAFT 0.496    
MAAT/MPH-ABT/Placebo  0.055 0.511 0.789  
 
BLT  0.517    
MAAT/MPH-ABT/Placebo  0.078 0.447 0.719  
MAAT/MPH-MAAT/Placebo  0.021 0.603 0.745  
MAAT/MPH-ABT/MPH  0.030 0.550 0.680  
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